"Janus Kinase 3" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A Janus kinase subtype that is predominantly expressed in hematopoietic cells. It is involved in signaling from a broad variety of CYTOKINE RECEPTORS including ones that utilize the INTERLEUKIN RECEPTOR COMMON GAMMA SUBUNIT.
| Descriptor ID |
D053616
|
| MeSH Number(s) |
D08.811.913.696.620.682.725.124.300 D12.776.476.393.300
|
| Concept/Terms |
Janus Kinase 3- Janus Kinase 3
- Kinase 3, Janus
- JAK-3 Protein Tyrosine Kinase
- JAK 3 Protein Tyrosine Kinase
- JAK3 Protein Tyrosine Kinase
|
Below are MeSH descriptors whose meaning is more general than "Janus Kinase 3".
Below are MeSH descriptors whose meaning is more specific than "Janus Kinase 3".
This graph shows the total number of publications written about "Janus Kinase 3" by people in this website by year, and whether "Janus Kinase 3" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1997 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 2 | 2 |
| 2001 | 0 | 1 | 1 |
| 2003 | 0 | 2 | 2 |
| 2011 | 1 | 0 | 1 |
To return to the timeline,
click here.
Below are the most recent publications written about "Janus Kinase 3" by people in Profiles.
-
LNK/SH2B3 regulates IL-7 receptor signaling in normal and malignant B-progenitors. J Clin Invest. 2016 Apr 01; 126(4):1267-81.
-
JAK3/STAT6 Stimulates Bone Marrow-Derived Fibroblast Activation in Renal Fibrosis. J Am Soc Nephrol. 2015 Dec; 26(12):3060-71.
-
Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemia. Blood. 2014 Aug 28; 124(9):1460-72.
-
Frequency and prognostic implications of JAK 1-3 aberrations in Down syndrome acute lymphoblastic and myeloid leukemia. Leukemia. 2011 Aug; 25(8):1365-8.
-
Preclinical characterization of atiprimod, a novel JAK2 AND JAK3 inhibitor. Invest New Drugs. 2011 Oct; 29(5):818-26.
-
JAK mutations in high-risk childhood acute lymphoblastic leukemia. Proc Natl Acad Sci U S A. 2009 Jun 09; 106(23):9414-8.
-
Autocrine release of interleukin-9 promotes Jak3-dependent survival of ALK+ anaplastic large-cell lymphoma cells. Blood. 2006 Oct 01; 108(7):2407-15.
-
Suppressor of cytokine signaling 3 expression in anaplastic large cell lymphoma. Leukemia. 2004 Nov; 18(11):1872-8.
-
Janus kinase 3 (JAK3) deficiency: clinical, immunologic, and molecular analyses of 10 patients and outcomes of stem cell transplantation. Blood. 2004 Mar 15; 103(6):2009-18.
-
Characterization and analysis of the proximal Janus kinase 3 promoter. J Immunol. 2003 Jun 15; 170(12):6057-64.